

Heal the heart with innovative science.

Capital Structure

Common Shares Outstanding	65.1 M
Fully Diluted Common Shares	85.5 M
Insider & Employee Ownership	11%
Cash and Cash Equivalents as of September 30, 2023	C\$40.5 M
Current Debt	C\$0.0 M

Leadership

David Elsley, MBA

President & Chief Executive Officer

Andrew Hamer, MBChB

Chief Medical Officer and Head of R&D

Chris Waddick, MBA, CPA, CMA

Chief Financial Officer

Bernard Lim, MIET, CEng (UK)

Chief Operating Officer

John Geddes, MBA

VP of Business Development

Andrea Parker, MSc, PhD

Senior Director of Clinical Operations

Anne Tomalin, BA, BSc, RAC

Director of Regulatory & Quality

Board of Directors

Guillermo Torre-Amione, MD, PhD Chairman

David Elsley, MBA

Chris Waddick, MBA, CPA, CMA

Jennifer M. Chao, BA

Teri Loxam, MBA

Peter Pekos, BSc, MSc

Colin G. Stott, BSc (Hons)

Michael J. Willner, Esq.

Developing Novel Therapeutic Approaches for Patients With Underserved Heart Disease

We are a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease.



Lead Asset in Clinical Development

CardiolRx[™], oral drug candidate, in Phase II trials for recurrent pericarditis and acute myocarditis.



Broad Exclusivity Protection

Comprehensive intellectual property portfolio. Eligible to pursue FDA orphan drug and EMA orphan medicine designations for Cardiol Rx^{TM} .



Scientific Rationale

Compelling evidence demonstrating the anti-inflammatory and anti-fibrotic properties of Cardiol Rx^{m} in myopericardial diseases.



Leadership

Experienced Management team, Board of Directors, and Scientific Advisory Board, with extensive expertise in developing therapeutics for inflammatory heart disease.



Innovative Research

Advancing the development of CRD-38, a novel proprietary subcutaneously administered pharmaceutical intended for use in heart failure.



Strong Financial Position

Debt-free and well-capitalized to achieve corporate milestones into 2026.

Our Focus

We are focused on understanding how inflammation and fibrosis contribute to diseases of the heart and to develop therapies, now in clinical trials for rare cardiac conditions, to target these mechanisms and promote healing.

Recurrent Pericarditis

Currently enrolling in a Phase II openlabel pilot study (MAvERIC-Pilot) investigating the tolerance, safety, and efficacy of CardiolRx™ in patients with recurrent pericarditis. The study will also assess the improvement in objective measures of disease, and during an extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids, while taking CardiolRx™.

Acute Myocarditis


Currently enrolling in a Phase II multinational trial (ARCHER) designed to study the safety and tolerability of CardiolRx™, as well as its impact on myocardial recovery, in patients presenting with acute myocarditis. ARCHER is expected to enroll 100 patients at major cardiac centers in North America, Europe, Latin America, and Israel.

Heart Failure

Advancing our novel subcutaneously administered drug formulation of cannabidiol as a potential anti-fibrotic and anti-inflammatory therapy intended for use in heart failure. Heart failure is a leading cause of death in the developed world, with associated annual healthcare costs in the United States exceeding \$30 billion annually.

Product Pipeline

Developing drug candidates that attenuate multiple inflammatory signaling pathways, including inhibiting activation of the NLRP3 inflammasome, known to play an important role in the inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.



- CardiolRx™ (cannabidiol) oral solution, is eligible for FDA orphan drug and EMA orphan medicine designations for recurrent pericarditis and acute myocarditis.
- CRD-38 (cannabidiol) subcutaneously administered formulation.

Major Milestones

- Phase II Recurrent Pericarditis Study
- Interim analysis.
- Complete 100% enrollment.
- Initiate Phase III Program*.
- Phase II Acute
 Myocarditis Study
- Complete 50% enrollment.
- Complete 100% enrollment.
- Report top-line data.

- 3 Subcutaneous Administered CRD-38
- Complete IND-enabling studies.
- Submit IND.
- Initiate Phase I clinical program.

*Subject to analysis of data from Phase II study

Cardiol Therapeutics Inc. +1 289.910.0850 NASDAQ: CRDL Toronto,
CardiolRx.com investor.relations@cardiolrx.com TSX: CRDL Ontario

This corporate fact sheet contains "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management. These forward-looking statements reflect management's current beliefs with respect to future events and are based on information currently available to management that are inherently subject to significant losks, uncertainties and competitive uncertainties and contingencies which could result in outcomes to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause the Company's actual results to be materially different from any future results that may be expressed or implied by such forward-looking statements. See the "Risk Factors" esction of the company's Annual Report on Form 20-F for the fiscal year ended December 31, 2022 (which may be viewed at www. secd.gov). Information contained in this corporate fact sheet is qualified in its entirety by such public filings. The Company makes no expressed or implied representation or warranty as to the accuracy or completeness of the information contained herein (including but not limited to projections of future performance). All summaries and discussions of documentation and/or financial information contained herein are qualified in their entirety by reference to the actual documents and/or financial statements. Data from third-party sources speak as of their original publication dates and the opinions and market data expressed in those reports are subject to change without notice. Third-party reports referenced have not been independently verified by the Company. This corporate fact sheet does not constitute an offer to sell any class of securities of the Company from from from formation purposes.